Alimta and Gemcitabine in Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The aims of this study are: (1) to assess the safety and activity of gemcitabine plus Alimta
(pemetrexed) regimen (GA regimen) in patients with advanced NSCLC patients in the context of
a randomized trial, and (2) to compare the GA with the paclitaxel plus gemcitabine (PG
regimen) in terms of toxicity and QoL